Oxford BioDynamics (LSE:OBD) Debt-to-Asset : 0.54 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Oxford BioDynamics Debt-to-Asset?

Oxford BioDynamics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £0.84 Mil. Oxford BioDynamics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £5.17 Mil. Oxford BioDynamics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was £11.07 Mil. Oxford BioDynamics's debt to asset for the quarter that ended in Mar. 2024 was 0.54.

Oxford BioDynamics Debt-to-Asset Historical Data

The historical data trend for Oxford BioDynamics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Debt-to-Asset Chart

Oxford BioDynamics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.43

0.54

0.40

Oxford BioDynamics Semi-Annual Data
	Sep13	Sep14	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.44	0.54	0.40	0.40	0.54

Competitive Comparison of Oxford BioDynamics's Debt-to-Asset

For the Biotechnology subindustry, Oxford BioDynamics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioDynamics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Debt-to-Asset falls into.

Oxford BioDynamics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Oxford BioDynamics's Debt-to-Asset for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.818	+	5.621)	/	16.127
	=	0.40

Oxford BioDynamics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.84	+	5.165)	/	11.066
	=	0.54

Oxford BioDynamics (LSE:OBD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Oxford BioDynamics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioDynamics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (LSE:OBD) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

OXBOF:USA LMQ:Germany

Address

Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB

Website

https://www.oxfordbiodynamics.com

Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.

Oxford BioDynamics Headlines

No Headlines